Novavax stock analysis
Want to see NVAX full AI Analyst Report?
Novavax (NVAX) Stock Price & Analysis
NVAX Stock Chart & Stats
- Day’s Range
- $7.88 - $8.14
- 52-Week Range
- $6.20 - $13.39
- Previous Close
- $8.06
- Volume
- N/A
- Average Volume (3M)
- 6.96M
- Market Cap
- $1.31B
- Enterprise Value
- $1.46B
- Total Cash (Recent Filing)
- $622.36M
- Total Debt (Recent Filing)
- $295.26M
- Price to Earnings (P/E)
- ―
- Beta
- 1.59
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sanofi Partnership Monetization
The Sanofi alliance provides Novavax with meaningful non-product revenue, milestone potential, and validation from a major vaccine partner. Additional technology-transfer and commercial-launch milestones, plus royalties, could support funding and diversify commercialization beyond standalone COVID vaccine sales.
Validated Matrix-M Platform
Matrix-M has progressed beyond a single experimental application into two commercial vaccines, demonstrating real-world platform utility and scale. That validation can improve partner interest, support licensing or supply opportunities, and create longer-term optionality across infectious-disease programs.
Cost Reduction And Cash Runway
Planned operating-cost reductions could materially lower the spending base and extend financial flexibility, while the stated runway reduces near-term financing pressure. If executed, the restructuring may allow Novavax to focus resources on commercial products, partnerships, and selected pipeline opportunities.
Bears Say
Volatile And Declining Revenue
The sharp reversal in revenue and earnings indicates that Novavax has not yet established a stable commercial scale. Such volatility makes planning and investment more difficult, while renewed losses can limit internally funded development and increase reliance on milestones or other external revenue sources.
Negative Shareholders’ Equity
A persistently negative equity base is a structural balance-sheet weakness rather than a temporary earnings fluctuation. It reduces financial resilience, makes leverage measures less favorable, and leaves less capacity to absorb setbacks or fund strategic initiatives without depending on operating improvement or partner-related cash inflows.
Persistent Cash Burn
Ongoing negative operating and free cash flow shows that the business is not currently self-funding its operations. Even with a stated cash runway, continued outflows increase dependence on milestones, product demand, cost reductions, or financing alternatives to sustain development and commercial activities over time.
Novavax News
Novavax Halts Omicron Booster Study, Raising Fresh Questions for NVAX Investors
Novavax ($NVAX) announced an update on their ongoing clinical study. Novavax has updated a Phase 4 U.S. study called “A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the
NVAX FAQ
What was Novavax’s price range in the past 12 months?
What is Novavax’s market cap?
When is Novavax’s upcoming earnings report date?
How were Novavax’s earnings last quarter?
Is Novavax overvalued?
Does Novavax pay dividends?
What is Novavax’s EPS estimate?
How many shares outstanding does Novavax have?
What happened to Novavax’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novavax?
What is the TipRanks Smart Score and how is it calculated?
Novavax Stock Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Charles Jacobs
- Employees
- 749
- Website
- www.novavax.com
- Address
- 21 Firstfield Road, Gaithersburg, MD, 20878, US
Novavax (NVAX) Earnings & Revenues
NVAX Company Deck
NVAX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial progress in Sanofi partnership milestones, commercial activity, cash runway, cost reductions, revenue guidance, Matrix-M demand, and pipeline development. The main challenges were lower quarterly revenue due to declining R&D reimbursement, uncertainty around future COVID market dollars and partner timelines, potential non-cash write-offs, and the early-stage nature of the C. diff and oncology programs. Highlights significantly outweighed the lowlights.
View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |













